Trial Profile

Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enfortumab vedotin (Primary) ; Erdafitinib (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Transitional cell carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions

Most Recent Events

06 Feb 2026 Planned number of patients changed from 30 to 24.
20 Oct 2025 Status changed from recruiting to active, no longer recruiting.
09 Sep 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com